ASH 2025 | Real-world outcomes of varnimcabtagene autoleucel in B-cell lymphoma and toxicity challenges

We have one CAR-T abstract that I think that’s a multicentric study or one named cabtagene autoleucel on lymphoma. Actually, I’m just a co-author on that. But this is one abstract that I’m really excited about. This is something which has, I mean, this has been a work that I’ve been closely associated with and we’ve been doing this. I mean, this has sort of become a standard of care ever since we started work on this project. And I mean, we’re quite happy with this work in the sense that we, at least the salvage chemotherapy is something we were interested. We didn’t want to, we wanted to make sure that the patients, you know, get an MRD negative, maybe after one or two cycles. What was interesting is that most of the patients could reach a CR after one cycle and about 85% of these patients could get MRD negative, could become MRD negative after one cycle, one or two cycles. And the only issue that I see with this protocol as of now is that there’s a significant number of VOD, which is a little higher than what is reported at around 25%. Most of it was about grade 1 and 2. But again, we had about out of that 25%, about half of them were about grade 3, which is of concern because, again, because of lack of access to defibrotide in India, it is not available, which is the drug for treatment for VOD. So this is the one concern which I see with this protocol. Otherwise, it has been quite good. And I mean, it is a very good alternative to just using single agent antithymoma, which was the original, which was actually originally devised to be used as single agent for relapsed refractory AL. So we use this drug in patients with relapsed refractory AL and those who are just MRD positive just to reach MRD negativity prior to transplant.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.